October 1, 2020 -- Ionis Pharmaceuticals and Genuity Science have entered a multiyear collaboration to accelerate the discovery and development of genetically validated targets for up to 20 diseases.
The partnership will leverage Genuity's whole-genome sequencing and deep phenotypic data to better define underlying disease mechanisms. This will be paired with Ionis' proprietary antisense technology for direct translation of targets into RNA-targeted therapeutics.
Under the agreement, Genuity will receive a combination of upfront payments and development milestones plus product royalties.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
